Clinical trials have shown the activity of the PARP inhibitor talazoparib in patients with BRCA-mutated cancers; [23, 26, 38] however, neither the inhibition of PAR nor the predicted damage to DNA has previously been demonstrated within patient tumor tissues. This evidence concerns the gene PARP1 and neoplasm.